Metraipolis › archive › dc_fe25d1c798e4

Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system — Europe PMC PMID:41586108

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41586108
DOI
10.3389/fneur.2025.1691324
License (as archived)
solo-consultazione
Archived
2026-11-06T23:12:20.205Z
SHA-256 of the archived text
712c53c8a17789d97f89d2da0769b3ca8d30e603b57762b09966914c9662a8d9
Stable URL of this page
https://metraipolis.com/documento/dc_fe25d1c798e4

How to cite

Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system — Europe PMC PMID:41586108 — Europe PMC (en), https://europepmc.org/article/MED/41586108 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe25d1c798e4 (Metraipolis archive dc_fe25d1c798e4, sha256 712c53c8a17789d97f89d2da0769b3ca8d30e603b57762b09966914c9662a8d9)
BibTeX
@misc{dcfe25d1c798e4,
  title = {Neurological adverse events of ROS1 inhibitors for non-small cell lung cancer: data from the FDA adverse event reporting system — Europe PMC PMID:41586108},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41586108},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe25d1c798e4; sha256 712c53c8a17789d97f89d2da0769b3ca8d30e603b57762b09966914c9662a8d9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41586108. Agents can read the archived copy with the MCP tool read_document.